ReviewInternational journal of molecular sciences2022
Statins Neuromuscular Adverse Effects.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Meta-analysis of factors for osteonecrosis in systemic lupus erythematosus: integration of comprehensive literatures and multicenter databases.Frontiers in immunology · 2026Pooled it
- Barriers and Facilitators of Exercise Rehabilitation in Patients With Myocardial Infarction Based on an Updated Consolidated Framework for Implementation Research: A Systematic Review.Reviews in cardiovascular medicine · 2025Pooled it
- Lipid-lowering statins and polyphenol-based supplementation: a scoping review on drug-food interaction potential.Frontiers in pharmacology · 2025Pooled it
- Severe Rosuvastatin-Associated Rhabdomyolysis and Dialysis-Requiring Acute Kidney Injury in an Octogenarian Patient: A Case Report.The American journal of case reports · 2026Article
- Co-Supplementation of Policosanol and Atorvastatin Attenuates High-Cholesterol and High-Galactose Diet-Induced Ocular and Brain Damage and Improves Cognitive Health in Zebrafish.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Reducing CETP activity prevents memory decline in an Alzheimer's disease mouse model.EMBO molecular medicine · 2026Article
- Myopathies in clinical care: a focus on treatable causes.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Association Between Statin Initiation and Myasthenia Gravis Crisis.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Mitochondrial homeostasis in bone aging: Unraveling dysfunctional pathways and developing precision therapies.Fundamental research · 2026Review
- Myasthenia gravis following the initiation of statin therapy: A multinational self-controlled case series study.Journal of internal medicine · 2026Observational
- Article
- Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy.Nutrients · 2026Review
- Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication.Frontiers in medicine · 2026Article
- A comprehensive study on the underlying mechanisms of the lipid-lowering effects of Bao Li Er Capsule in hyperlipidemia.Journal of traditional and complementary medicine · 2026Article
- Hypercholesterolemia Successfully Treated With Two Different PCSK9 Inhibitors in a Patient With Glycogen Storage Disease IXd: Phosphorylase Kinase Deficiency.Journal of lipid and atherosclerosis · 2026Article
- Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management.Cardiovascular therapeutics · 2026Review
- Network Pharmacology and Experimental Validation of the Anti-Inflammatory Effect of Modified Qianzheng Powder in Atherosclerosis.Combinatorial chemistry & high throughput screening · 2026Article
- Screening of Anti-Atherosclerosis Targets of Ce-Bai-Si-Wei Decoction Based on Multidimensional Data and Study on Cellular Distribution.Journal of diabetes research · 2026Article
- Statin-Associated Headache: A Rare and Underrecognized Clinical Presentation: A Case Report.Reports (MDPI) · 2025Article
- Network Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment.Journal of cardiovascular translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.